Bringing New Cancer Drugs to Market with Founder & CEO, Lewis Bender

In this episode, our guest is Lewis Bender, Chairman, and CEO, of Intensity Therapeutics’ Founder which is a late-stage clinical biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while training the patient’s immune system to fight the cancer. The Company’s lead product candidate, INT230-6, is currently in human clinical studies to treat refractory solid tumors. Talking points: Milestone Achievement: "Congratulations on dosing the first patient in the INVINCIBLE-4 Phase 2 clinical trial for triple-negative breast cancer. Can you walk us through the significance of this milestone and what it means for the future of Intensity Therapeutics?" Innovative Approach of INT230-6: "Intensity Therapeutics focuses on developing cancer treatments that not only attenuate tumors with minimal side effects but also train the immune system to fight cancer. Could you explain how your lead product, INT230-6, achieves this unique approach and what differentiates it from existing cancer therapies?" Collaboration with SAKK: "Your partnership with The Swiss Group for Clinical Cancer Research (SAKK) is a key component of the INVINCIBLE-4 study. How does this collaboration enhance your clinical development efforts, and what are you hoping to achieve together in this trial?" Impact on Triple-Negative Breast Cancer (TNBC): "Triple-negative breast cancer is known for being particularly aggressive and having limited treatment options. How does INT230-6 address the unmet needs of TNBC patients, and what potential impact do you foresee it having on improving patient outcomes?" Future Vision and Next Steps: "Looking ahead, what are the next steps for Intensity Therapeutics following the initiation of the INVINCIBLE-4 study? How do you envision the future of your company in the evolving landscape of cancer therapeutics?" Guest - Lewis Bender Host - Hillary Blackburn, PharmD, MBA @talktoyourpharmacist for Instagram and Facebook ★ Support this podcast on Patreon ★

You can listen to Bringing New Cancer Drugs to Market with Founder & CEO, Lewis Bender online on Radio and Podcast. Open the player on this page to stream the available audio.

Bringing New Cancer Drugs to Market with Founder & CEO, Lewis Bender is an episode from Talk to Your Pharmacist by Pharmacy Advisory Group.

This episode is 34:53 long.

This episode was published on Apr 6, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Talk to Your Pharmacist when more episodes are available from the podcast feed.